Home
Issues
Aim & Scope
Open Access
Indexing
Why publish with us
Contact
Editorial Board
Instructions to Authors (PDF)
Manuscript Types
Manuscript Formatting
How to submit
Preprints
Authorship & COI
Principles of Transparency Checklist
Publication Ethics and Publication Malpractice Statement
CrossMark
Data Policies
EDITORIAL
The role of c-Src in lung cancer, its metastasis and anti-cancer therapy Editorial Cancer
1
Pneumonology Clinic, General Hospital of Serres
Pneumon 2011;24(2):131-135
KEYWORDS
REFERENCES (30)
1.
Yilmaz M, Christofori G, Lehembre F. Distinct mechanisms of tumor invasion and metastasis. Trends in Molecular Medicine, 2007; Vol. 13, No 12.
2.
Guo G, Giancotti FG. Integrin signaling during tumor progression. Nat Rev Mol Cell Biol, 2004;5:816-826.
3.
Tzouvelekis A, Karameris A, Bouros D. Telomeres, telomerase and immortality: A common link between lung cancer and pulmonary fibrosis. Pneumon, 2007;20:312-317.
4.
Papalimneou V, Charalambopoulos C. Adhesion molecules and lung cancer. Pneumon, 2001;14:109-117.
6.
Mitra SK, Schlaepfer D. Integrin-regulated FAK-Src signaling in normal and cancer cells. Current opinion in Cell Biology, 2006;18:516-523.
7.
Thomas SM, Brugges JS. Cellular functions regulated by Src family kinases. Ann Rev Cell Dev Biol, 1997;2:467-475.
8.
Courtneidge SA. Role of Src in signal transduction pathways. Biochemical Society Transactions, 2002; Vol. 30, part 2.
9.
Tatosyan AG, Mizenina OA. Kinases of the Src family: Structure and functions. Biochemistry, 1999;65:49-58.
10.
Bjorge JD, Jakymiw A, Fujita JD. Selected glimpses into the activation and function of Src kinase. Oncogene 2000;19:5620-5635.
11.
Lowell CA, Soriano P. Knockouts of Src-family kinases: stiff bones, wimpy T cells, and bad memories. Genes Dev, 1996;10:1845-1857.
12.
Irby BR, Yeatman JT. Role of Src expression and activation in human cancer. Oncogene 2000;19:5636-5642.
13.
Carney DN, Gazdar AF, Bepler G, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res, 1985;45:2913-23.
14.
Mazurenko NN, Kogan AE, Zborovskaya BI, Kisseljov LF. Expression of pp60c-src in human small cell and non-small cell lung carcinomas. Eur J. Cancer, 1992;Vol. 28, No 2/3:372-377.
15.
Masaki T, Igarashi K, Tokuda M, et al. pp60c-src activation in lung adenocarcinoma. European Journal of Cancer, 2003;39: 1447 1455 Inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol, 2010;28:1387-1394.
17.
Playford MP, Schaller MD. The interplay between Src and integrins in normal and tumor biology. Oncogene, 2004;23:7928-7946.
18.
Cance WG, Harris JE, Iacocca MV, et al. Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes. Clin Cancer Res, 2000;6:2417-2423.
19.
Meng XN, Jin Y, Yu Y, et al. Characterization of fibronectinmediated FAK signaling pathways in lung cancer cell migration and invasion. British journal of cancer, 2009;101:327-334.
20.
Byers LA, Sen B, Saigal B, et al. Reciprocal regulation of cSrc and STAT3 in non-small cell lung cancer. Clin Cancer Res 2009;15:6852-61. Epub 2009 Oct 27.
21.
Giaccone G, Zucali PA. Src as a potential therapeutic target in non-small-cell lung cancer. Annals of Oncology, 2008;19:1219- 1223.
22.
Song L, Morris M, Bagui T, Lee Y F, Jove R, Haura BE. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res, 2006; 66:(11).
23.
Kim JI, Lakshmikanthan V, Frilot N, Daaka Y. Prostaglandin E2 promotes lung cancer cell migration via EP4-betaArrestin1-c-Src signalsome. Mol Cancer Res 2010;8:569-77. Epub 2010 Mar 30. PubMed PMID: 20353998; PubMed Central PMCID: PMC2855782.
24.
Lee D, Gautschi O. Clinical development of Src tyrosine kinase inhibitors in lung cancer. Clinical lung cancer, 2006;7:6:381-384.
25.
Rothschild SI, Gautschi O, Haura EB, Johnson FM. Src inhibitors in lung cancer: current status and future directions. Clin Lung Cancer 2010;11(4):238-42. Review. Pub Med PMID: 20630825.
26.
Aleshin A, Finn SR. Src: a century of scince brought to the clinic, 2010;18:8:599-607.
27.
Tsai YM, Yang CJ, Hsu YL, et al. Glabridin inhibits migration, invasion, and angiogenesis of human non-small cell lung cancer A549 cells by inhibiting the FAK/Rho signaling pathway. Integr Cancer Ther, 2010; 1-9 (in press).
28.
Zhang J, Kalyankrishna S, Wislez M, et al. SRC-family kinases are activated in non–small cell lung cancer and promote the survival of epidermal growth factor receptor–dependent cell lines. Am J Pathol, 2007;170:366–376.
29.
Haura EB, Tanvetanyon T, Chiapori A. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol, 2010; 28: 1387-1394.
30.
Johnson FM, Tang X, Tran H, et al. Phase II study of dasatinib in non-small lung cancer (NSCLC). J Clin Oncol, 2009.
Share
RELATED ARTICLE
| eISSN: | 1791-4914 |
| ISSN: | 1105-848X |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
